The Democratic Republic of Congo's Bundibugyo-virus Ebola outbreak has reached 5,794 confirmed cases and 2,786 deaths as of August 26 — a 48.1 percent case-fatality ratio across 60 health zones in six provinces — making it the largest and deadliest Ebola outbreak the country has ever recorded, regardless of which Ebola virus species is being compared. [1] The World Health Organization's latest Disease Outbreak News update confirms the milestone formally, but frames it primarily through case-fatality-ratio methodology and granular health-zone counts rather than leading with the historic threshold itself. [1]
The scale of the outbreak's growth since this paper last covered it is severe. On July 30, this paper reported the outbreak passing 1,500 dead in record time, citing a ministry count of 3,442 confirmed cases and 1,521 deaths as of July 28, alongside WHO's caveat that the cumulative ledger included significant backfill from earlier, undercounted cases. In the four weeks since, confirmed cases have grown by roughly 68 percent and deaths by roughly 83 percent, formally exceeding the country's prior worst outbreak — the 2018-2020 eastern Congo epidemic, which reported 3,317 cases over nearly two years. [1][2] The current outbreak reached that scale, and far surpassed it, within roughly three and a half months of its first confirmed case in Mongbwalu health zone, Ituri Province, on May 14.
WHO's own numbers show the milestone was not sudden. The organization's August 14 update — the prior Disease Outbreak News bulletin — put the toll at 4,665 confirmed cases and 2,184 deaths as of August 12, a 46.8 percent case-fatality ratio already exceeding the country's 2018-2020 case count. [3] The formal announcement of the deadliest-outbreak milestone, in other words, trailed the underlying data by roughly two weeks — and X users tracking the outbreak's toll moved faster than either WHO's biweekly bulletin cycle or most Western wire coverage. Reuters Africa posted on August 16 that the outbreak "has killed 2325 people, government data showed on Sunday, surpassing the toll from the 2018-" prior epidemic, flagging the historic threshold roughly ten days before WHO's own August 26 confirmation folded the milestone into its routine case-count update. [3]
Ituri Province remains the outbreak's epicenter, accounting for 4,802 of the 5,794 confirmed cases nationwide — more than 80 percent of the total — with North Kivu now the second-most affected province at 775 cumulative cases, up sharply from the smaller provincial footprint the outbreak carried when this paper last checked its spread in late July. [1] North Kivu has also recorded the highest case-fatality ratio of any affected province, at 68 percent, a figure WHO says is under investigation to determine why mortality there runs so far above the outbreak's overall rate. [1] Six additional health zones have reported cases since WHO's prior bulletin, including Bas-Uélé province's Ganga and Viadana health zones and North Kivu's Biena and Manguredjipa zones — geographic expansion WHO attributes to a mix of continued transmission and improved surveillance capacity picking up cases that would previously have gone undetected. [1]
The strain driving the outbreak is what makes both the WHO bulletin's clinical caution and X's faster-moving case-count tracking incomplete on their own. Bundibugyo virus disease is caused by a distinct Ebola virus species from the Zaire strain responsible for most prior major outbreaks, including the one for which the licensed vaccine Ervebo was developed and tested. [1][3] No vaccine or specific antiviral treatment is currently approved for Bundibugyo virus disease, and it remains genuinely unknown whether Ervebo — designed against a different species — provides meaningful protection against this outbreak's strain. [1] On August 27, health authorities nonetheless began vaccinating health care workers with Ervebo in parts of the country, including Kisangani in Tshopo province, alongside a parallel randomized clinical trial designed to generate the evidence that does not yet exist. [1]
That trial builds on groundwork this paper flagged in July. The WHO Technical Advisory Group on candidate vaccine prioritization recommended on August 7 that Ervebo be prioritized for inclusion in a randomized study given the absence of any purpose-built alternative, and the International Coordinating Group on Vaccine Provision subsequently allocated 70,000 doses to the country in two streams: 20,000 for the clinical trial itself and 50,000 for direct protection of frontline and health workers deemed at highest occupational risk. [3] Health-worker infections have been substantial throughout the outbreak — at least 155 confirmed cases among health workers as of early August, including 45 deaths, a 29 percent case-fatality ratio among medical staff that WHO attributes partly to inconsistent infection-prevention practices outside dedicated Ebola treatment centers. [3]
WHO's risk assessment, last updated August 14, rates the risk within the Democratic Republic of Congo as "very high," citing continued transmission, geographic expansion into new health zones, and the possibility that the case-fatality ratio could climb further as additional deaths are investigated and confirmed. [1] The risk to countries sharing land borders with the country — chiefly Uganda, the Central African Republic and South Sudan — is rated "high," driven by cross-border trade, mining-related population mobility, and, for the Central African Republic and South Sudan specifically, compounding humanitarian crises and weaker health-system capacity. [1] The global and broader-African-region risk remains rated "low." [1]
The outbreak is also unfolding inside a humanitarian emergency that predates it and is actively obstructing the response. More than 26 million people in the country face acute food insecurity, and an estimated one million people are internally displaced within Ituri Province alone — the same province bearing 80 percent of the outbreak's case burden. [1] WHO's bulletin documents twelve confirmed attacks on health care facilities since the outbreak was declared a public health emergency of international concern in May, with additional reports still under verification, and describes insecurity as actively curtailing response-team access, discouraging patients from seeking care, and disrupting the surveillance systems needed to catch new cases before they spread further. [1] Contact tracing, a core tool for interrupting transmission chains, reached 82.3 percent of the roughly 26,850 contacts requiring monitoring as of August 26 — a workload that has grown alongside the outbreak itself and now exceeds the tracing burden this paper reported in July by a wide margin. [1]
A parallel treatment trial is running alongside the vaccine effort, though its findings will not arrive in time to help most of this outbreak's patients. The PARTNERS trial, sponsored by WHO to identify effective treatments specifically for Bundibugyo virus disease, began enrollment July 2 across three clinical facilities in Ituri Province and had enrolled more than 250 confirmed cases as of the August 26 update, up from just over 100 when this paper last checked the outbreak's status in July. [1] No treatment has yet been shown effective against the Bundibugyo strain specifically; the trial exists precisely because supportive care protocols developed for the more common Zaire strain cannot be assumed to translate.
WHO's global surveillance apparatus has also been working overtime to keep the outbreak from spreading undetected beyond the region it already dominates. Between May 18 and August 28, WHO's enhanced public health intelligence system identified 76 Ebola-related signals across 23 countries and territories — suspected cases among travelers and health workers, plus reports circulating in public sources — each requiring rapid verification and risk assessment through national health authorities. [1] Of those 76 signals, 92 percent were ultimately ruled out through investigation and laboratory testing; only six were confirmed as genuine Ebola events, a ratio that illustrates both the scale of false-alarm noise generated by a high-profile outbreak and the volume of genuine verification work WHO's regional offices are absorbing to keep that noise from becoming a second front. [1]
Two adjacent developments offer the response's clearest positive signal. Uganda formally ended its own linked outbreak on August 27, completing the 42-day enhanced-monitoring period following its last patient's discharge without a single additional locally transmitted case; France reached the same milestone for its single imported case around the same time. [1] Both closures demonstrate that Bundibugyo virus disease transmission chains can be interrupted decisively once a case is isolated and its contacts traced — the exact capability the Democratic Republic of Congo's own response is straining to scale to an outbreak now running at 60 times Uganda's total case count.
The gap between X's faster informal, crowdsourced tracking and WHO's slower, methodical, caveat-heavy bulletin cycle is not simply a story about who managed to publish a striking number first. It is a divergence in what each side treats as the headline. X flagged the historic death toll the moment government data crossed the threshold; WHO's biweekly bulletin, when it caught up, buried the milestone inside case-fatality-ratio percentages and health-zone counts, treating the number as one data point among many rather than the story itself. Both undersell, in their own way, that the outbreak reshaping those numbers is being fought without a vaccine anyone can say, with confidence, actually works against it.
-- KENJI NAKAMURA, Tokyo